IL6 and colitis: Intraperitoneal injection of these vesicles to mice treated with TNBS decreases the level of the pro-inflammatory cytokines IL-6, IL-1β, IFN-γ and IL-17a and increases the level of the anti-inflammatory cytokine IL-10 in colonic tissue, thus preventing colitis development [121].